IceCure Medical (ICCM) Stock Overview
A commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ICCM Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
IceCure Medical Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.08 |
| 52 Week High | US$42.00 |
| 52 Week Low | US$2.12 |
| Beta | 1.54 |
| 1 Month Change | -48.32% |
| 3 Month Change | -62.48% |
| 1 Year Change | -90.03% |
| 3 Year Change | -91.58% |
| 5 Year Change | -92.10% |
| Change since IPO | -4.41% |
Recent News & Updates
ICCM: Expanding Global Cryoablation Adoption Will Drive Future Upside Potential
Analysts have updated their price target on IceCure Medical to $30.00, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their valuation models. What’s in the News for IceCure Medical IceCure Medical expanded its United States sales and marketing teams, adding dedicated personnel in territories including New York, Southern California and the Midwest, along with extra clinical support to help train sites and support adoption of the ProSense system for breast cancer cryoablation.
ICCM: Legal Overhang And Nasdaq Compliance Efforts Will Shape Upside Potential
Analysts now value IceCure Medical at an updated fair value of $31.50 per share, up from $2.45, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E multiples that have significantly increased their price target framework. What's in the News for IceCure Medical IceCure Medical received a Tel Aviv District Court decision approving the certification of a shareholder class action related to a 2021 private placement, with the company stating it believes the claims are without merit and that it intends to defend itself vigorously.
ICCM: Japanese Breast Cancer Opportunity Will Drive Future Upside Potential
Analysts have updated their price target for IceCure Medical from $3.13 to $30.50, citing revised assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. What's in the News for IceCure Medical IceCure Medical highlighted a new peer-reviewed article in the International Journal of Surgery comparing cryoablation with radiofrequency ablation for early-stage breast cancer, ahead of its participation in the 34th Annual Meeting of the Japanese Breast Cancer Society in Kyoto, Japan, on June 25-27, 2026.Recent updates
ICCM: Expanding Global Cryoablation Adoption Will Drive Future Upside Potential
Analysts have updated their price target on IceCure Medical to $30.00, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their valuation models. What’s in the News for IceCure Medical IceCure Medical expanded its United States sales and marketing teams, adding dedicated personnel in territories including New York, Southern California and the Midwest, along with extra clinical support to help train sites and support adoption of the ProSense system for breast cancer cryoablation.ICCM: Legal Overhang And Nasdaq Compliance Efforts Will Shape Upside Potential
Analysts now value IceCure Medical at an updated fair value of $31.50 per share, up from $2.45, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E multiples that have significantly increased their price target framework. What's in the News for IceCure Medical IceCure Medical received a Tel Aviv District Court decision approving the certification of a shareholder class action related to a 2021 private placement, with the company stating it believes the claims are without merit and that it intends to defend itself vigorously.ICCM: Japanese Breast Cancer Opportunity Will Drive Future Upside Potential
Analysts have updated their price target for IceCure Medical from $3.13 to $30.50, citing revised assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. What's in the News for IceCure Medical IceCure Medical highlighted a new peer-reviewed article in the International Journal of Surgery comparing cryoablation with radiofrequency ablation for early-stage breast cancer, ahead of its participation in the 34th Annual Meeting of the Japanese Breast Cancer Society in Kyoto, Japan, on June 25-27, 2026.FDA Breast Cancer Clearance And Reimbursement Progress Will Transform Long Term Cryoablation Adoption
Catalysts About IceCure Medical IceCure Medical develops and commercializes the ProSense cryoablation system for minimally invasive treatment of tumors, including low risk early breast cancer. What are the underlying business or industry changes driving this perspective?Regulatory And Reimbursement Delays Will Challenge Breast Cancer Adoption Yet Long Term Potential Will Build
Catalysts About IceCure Medical IceCure Medical develops and commercializes the ProSense cryoablation system for minimally invasive treatment of breast cancer and other tumors. What are the underlying business or industry changes driving this perspective?Shareholders May Find It Hard To Justify Increasing IceCure Medical Ltd's (NASDAQ:ICCM) CEO Compensation For Now
Key Insights IceCure Medical to hold its Annual General Meeting on 20th of August Total pay for CEO Eyal Shamir...Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Shareholder Returns
| ICCM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.5% | -0.7% | -1.0% |
| 1Y | -90.0% | -20.7% | 14.7% |
Return vs Industry: ICCM underperformed the US Medical Equipment industry which returned -20.7% over the past year.
Return vs Market: ICCM underperformed the US Market which returned 14.7% over the past year.
Price Volatility
| ICCM volatility | |
|---|---|
| ICCM Average Weekly Movement | 63.1% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ICCM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ICCM's weekly volatility has increased from 33% to 63% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 68 | Eyal Shamir | www.icecure-medical.com |
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors.
IceCure Medical Ltd Fundamentals Summary
| ICCM fundamental statistics | |
|---|---|
| Market cap | US$10.55m |
| Earnings (TTM) | -US$15.74m |
| Revenue (TTM) | US$3.57m |
Is ICCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICCM income statement (TTM) | |
|---|---|
| Revenue | US$3.57m |
| Cost of Revenue | US$2.26m |
| Gross Profit | US$1.30m |
| Other Expenses | US$17.05m |
| Earnings | -US$15.74m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.59 |
| Gross Margin | 36.55% |
| Net Profit Margin | -441.60% |
| Debt/Equity Ratio | 0% |
How did ICCM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/27 04:45 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IceCure Medical Ltd is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Anthony Vendetti | Maxim Group |